Oct 19, 2025 08:45AM
Oct 19, 2025 08:45AM
Sep 15, 2025 07:00AM
Jul 10, 2024 06:06AM
Apr 8, 2024 07:08AM
Apr 3, 2024 08:04AM
Apr 3, 2024 08:00AM REJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan Initiated in Patients with Platinum-Resistant Ovarian Cancer
Oct 22, 2023 04:15AM
May 25, 2023 05:00PM
Apr 20, 2023 09:00PM
Jan 26, 2023 02:00AM
Dec 19, 2022 02:00AM
Dec 7, 2022 08:36AM
Aug 5, 2022 08:06PM ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
Aug 5, 2022 08:00PM
Jul 25, 2022 02:00AM
Jun 22, 2022 02:00AM
Jun 5, 2022 08:10AM
Jun 5, 2022 08:00AM
May 23, 2022 08:00AM
Apr 27, 2022 07:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Breakthrough Therapy Designation in the US for patients with HER2-low metastatic breast cancer
Apr 26, 2022 09:00PM
Feb 21, 2022 02:00AM
Jul 27, 2020 06:11AM

66,637 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All